Syndax Pharmaceuticals Inc SNDX
We take great care to ensure that the data presented and summarized in this overview for Syndax Pharmaceuticals Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SNDX
View all-
Kynam Capital Management, LP Princeton, NJ8.52MShares$139 Million9.53% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$129 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.8MShares$94.7 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.03MShares$82.2 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.07MShares$66.4 Million3.84% of portfolio
-
Bank Of America Corp Charlotte, NC3.84MShares$62.7 Million0.0% of portfolio
-
State Street Corp Boston, MA3.44MShares$56.2 Million0.0% of portfolio
-
Stem Point Capital LP New York, NY2.37MShares$38.7 Million7.13% of portfolio
-
Franklin Resources Inc San Mateo, CA2.36MShares$38.5 Million0.01% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.13MShares$34.7 Million0.04% of portfolio
Latest Institutional Activity in SNDX
Top Purchases
Top Sells
About SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Insider Transactions at SNDX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 18
2025
|
Dennis Podlesak |
SELL
Open market or private sale
|
Direct |
19,200
-9.1%
|
$288,000
$15.84 P/Share
|
|
Aug 18
2025
|
Dennis Podlesak |
BUY
Exercise of conversion of derivative security
|
Direct |
19,200
+8.34%
|
$134,400
$7.2 P/Share
|
|
Aug 15
2025
|
Dennis Podlesak |
SELL
Open market or private sale
|
Direct |
19,200
-9.1%
|
$288,000
$15.54 P/Share
|
|
Aug 15
2025
|
Dennis Podlesak |
BUY
Exercise of conversion of derivative security
|
Direct |
19,200
+8.34%
|
$134,400
$7.2 P/Share
|
|
Aug 14
2025
|
Dennis Podlesak |
SELL
Open market or private sale
|
Direct |
19,200
-9.1%
|
$268,800
$14.19 P/Share
|
|
Aug 14
2025
|
Dennis Podlesak |
BUY
Exercise of conversion of derivative security
|
Direct |
19,200
+8.34%
|
$134,400
$7.2 P/Share
|
|
Jul 31
2025
|
Keith A. Goldan Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
1,226
+1.29%
|
$9,808
$8.43 P/Share
|
|
Jul 16
2025
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,534
-2.46%
|
$67,806
$9.29 P/Share
|
|
Jul 16
2025
|
Keith A. Goldan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,296
-1.38%
|
$11,664
$9.29 P/Share
|
|
May 19
2025
|
Keith Katkin |
BUY
Open market or private purchase
|
Direct |
10,000
+9.09%
|
$90,000
$9.11 P/Share
|
|
May 19
2025
|
Martin H. Huber Jr. |
BUY
Open market or private purchase
|
Direct |
5,000
+5.95%
|
$40,000
$8.99 P/Share
|
|
May 19
2025
|
Keith A. Goldan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+3.1%
|
-
|
|
May 16
2025
|
Nicholas A.J. Botwood Head of R&D, CMO |
BUY
Open market or private purchase
|
Direct |
11,765
+25.07%
|
$94,120
$8.99 P/Share
|
|
Mar 14
2025
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,074
+1.95%
|
$42,518
$7.2 P/Share
|
|
Mar 04
2025
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,814
-2.54%
|
$117,210
$15.05 P/Share
|
|
Mar 04
2025
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,814
+2.47%
|
$54,698
$7.2 P/Share
|
|
Feb 10
2025
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,288
-4.24%
|
$199,320
$15.5 P/Share
|
|
Feb 10
2025
|
Keith A. Goldan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,777
-4.0%
|
$56,655
$15.5 P/Share
|
|
Feb 10
2025
|
Neil Gallagher President, Head of R&D |
SELL
Open market or private sale
|
Direct |
4,618
-5.15%
|
$69,270
$15.5 P/Share
|
|
Feb 05
2025
|
Neil Gallagher President, Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
41,900
+21.25%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 433K shares |
|---|---|
| Exercise of conversion of derivative security | 71.5K shares |
| Open market or private purchase | 29.8K shares |
| Other acquisition or disposition | 1.23K shares |
| Open market or private sale | 95.9K shares |
|---|